Oncology Institute (TOI) Q1 2026: Pharmacy Revenue Jumps 78% on Capitated Lives Expansion
TOI’s Q1 showcased a decisive acceleration in specialty pharmacy growth and value-based care scale, as Florida profitability and a $20 million free cash flow swing signal an inflection in operational leverage and risk model validation. The ramp in delegated capitation and the upcoming provider portal launch set up further upside in pharmacy and ancillary services, with AI-driven cost controls boosting confidence in sustained margin progress. Investors should watch for execution on Florida expansion, attachment rates, and the portal’s impact on network provider engagement as the year unfolds.
Summary
- Pharmacy-Driven Margin Expansion: Record specialty pharmacy performance is now a primary profit engine.
- Capitated Model Validation: Florida achieves profitability, with delegated risk arrangements scaling rapidly.
- Technology Levers in Play: AI and provider portal initiatives are set to drive further operational efficiency and engagement.
Business Overview
The Oncology Institute (TOI) is a value-based oncology care platform operating across five states, generating revenue through capitated contracts, fee-for-service arrangements, and a rapidly scaling specialty pharmacy. Its major segments are patient services—comprising both capitated and fee-for-service models—and specialty pharmacy, which dispenses oncology drugs and related medications. TOI’s business model centers on managing cancer care costs while maintaining quality outcomes, leveraging risk-based contracts and ancillary services to drive growth and profitability.
Performance Analysis
TOI delivered robust Q1 revenue growth, fueled by a 78% year-over-year surge in specialty pharmacy revenue and a 54% increase in capitated patient services. Pharmacy now accounts for nearly 60% of total revenue, with the number of prescription fills more than doubling, even as average revenue per fill declined 12% due to evolving payer and patient mix. The Florida market reached profitability, validating the delegated capitation model and providing a template for broader geographic expansion.
Gross profit expanded alongside scale, but overall gross margin contracted by 80 basis points due to a mix shift toward lower-margin delegated contracts and the absence of a prior-year rebate. Patient services margins declined as the business absorbed new risk contracts and adopted more conservative reserves, while pharmacy margins remained stable at 19.2%, supported by procurement discipline and formulary management. Operating leverage was evident in SG&A, which fell to 19.1% of revenue, and adjusted EBITDA loss narrowed substantially, positioning TOI for full-year profitability. Cash flow inflected positively, with a $20 million swing in free cash flow guidance, driven by vendor renegotiations and scale benefits.
- Capitation Mix Shift: Capitated revenue now represents 45.6% of patient services, up from 33% a year ago, accelerating the transition to value-based care.
- Pharmacy Attachment Rates: Workflow changes and provider education drove higher-than-expected script attachment, boosting pharmacy volume and margin stability.
- Operating Efficiency Gains: AI-enabled initiatives in revenue cycle, prior auth, and call center are on track for $2 million in annual cost savings, with further upside potential.
TOI’s financial trajectory is increasingly tied to its ability to scale delegated risk, optimize pharmacy capture, and realize cost synergies from technology investments. The quarter’s results underscore a business model that is becoming more resilient and levered to managed care economics.
Executive Commentary
"Record Part B fills drove pharmacy revenue up 78% in the quarter compared to the first quarter of 2025, reflecting overall growth in patient encounters and continued operational execution on prescription fills. As a testament to the durability and replicability of our clinical model, we saved nearly $2 million in Medicare spending as part of the CMS Enhancing Oncology Model performance program in period three, increasing the savings generated from the previous period while maintaining the high-quality care we deliver to the members we serve in the community."
Dan Vernage, Chief Executive Officer
"Our expanded utilization management program, which we refer to as TOI Pathways, now covers our entire drug portfolio, including the pharmacy, versus historically only our Part B drugs. This continues to support margin state stability, and we see further opportunity in this area as we increase scale."
Rob Carter, Chief Financial Officer
Strategic Positioning
1. Florida Capitated Model Achievement
TOI’s Florida market is now profitable, marking a major milestone for the delegated capitation model, which involves taking fixed payments to manage patient care costs. The company is scaling to 200,000 Medicare Advantage lives across 25 counties, expanding both its clinic footprint and MSO (management services organization) network. This validates TOI’s approach to risk-bearing contracts and sets a foundation for further expansion in other states.
2. Pharmacy Platform as Growth Engine
The specialty pharmacy business is now the largest revenue contributor, with record script volumes and consistent gross margins. TOI’s ability to capture both Part B and, prospectively, Part D prescriptions from its delegated network is a unique lever, especially as the provider portal launches. Procurement optimization and workflow improvements are key to maintaining margin and driving incremental free cash flow as scale increases.
3. Technology and AI-Driven Efficiency
AI integration in revenue cycle management, prior authorization, and the call center is delivering cost savings and operational improvements. The upcoming provider portal is set to deepen network provider engagement, drive adherence to clinical pathways, and enable ancillary service uptake, all of which support margin improvement and risk management. These technology levers are central to TOI’s long-term margin expansion strategy.
4. Ancillary Services and Clinical Pathways
Ancillary offerings, including clinical trials and care navigation, are being integrated into the provider portal, creating new revenue streams and reinforcing TOI’s position as a comprehensive oncology care platform. Pathway adherence is a direct lever for medical loss ratio (MLR) control, which is already performing ahead of target in Florida.
5. Payer and Provider Network Expansion
TOI is actively negotiating with additional health plans beyond its current partners, aiming to expand its delegated capitation model both in Florida and other states. This broadens the addressable market and creates further upside for pharmacy and patient services segments.
Key Considerations
TOI’s Q1 results showcase a business in transition, leveraging scale and technology to move decisively toward sustainable profitability. The interplay between risk-based contracts, pharmacy capture, and operational efficiency is defining the company’s future trajectory.
Key Considerations:
- Delegated Capitation Scale: Florida’s rapid ramp demonstrates model viability, but execution in clinic build-out and network provider integration will be critical as new counties come online.
- Pharmacy Attachment and Margin: Continued improvement in provider workflow and attachment rates is necessary to maximize pharmacy economics and offset margin headwinds from delegated contracts.
- Provider Portal Impact: The Q3 launch is a pivotal test for driving pathway adherence, ancillary service uptake, and incremental pharmacy revenue, particularly for Part D scripts.
- AI and Cost Discipline: Early success in AI-driven savings suggests further runway, but realization of broader efficiencies beyond the initial $2 million target will be key for long-term margin expansion.
- Capital Structure and Liquidity: The ongoing convertible note refinancing is a watchpoint, as is the sustainability of positive free cash flow as the business scales delegated risk.
Risks
TOI faces execution risk as it rapidly scales its capitated model, particularly in Florida where clinic build-out and network management are underway. Pharmacy margin stability is exposed to drug pricing shifts and payer mix changes, while technology initiatives must deliver on promised savings. Regulatory shifts in Medicare Advantage and competitive responses from larger oncology networks could also impact growth and profitability. The pending refinancing of the convertible note adds a layer of financial uncertainty.
Forward Outlook
For Q2 2026, TOI guided to:
- Adjusted EBITDA in the range of a loss of $1 million to positive $1 million, with improvement expected as deductible resets and Florida ramp normalize seasonal headwinds.
For full-year 2026, management reaffirmed guidance:
- Revenue of $630 million to $650 million
- Gross profit of $97 million to $107 million
- Adjusted EBITDA of $0 to positive $9 million
- Free cash flow raised to $5 million to $15 million (from prior -$15 million to $5 million)
Management emphasized continued momentum in delegated capitation, pharmacy growth, and technology-driven cost savings as the main drivers of full-year performance.
- Pharmacy access expansion to delegated network members in Florida expected in H2, with upside not yet in guidance.
- Provider portal launch in Q3 to drive further engagement and ancillary revenue opportunities.
Takeaways
TOI’s Q1 performance underscores a business model at an inflection, with pharmacy and delegated capitation driving top-line and margin gains, while technology and operational discipline underpin a path to sustainable profitability.
- Pharmacy as Core Profit Lever: Attachment rate gains and scale economics are making specialty pharmacy the centerpiece of TOI’s earnings power.
- Risk Model Validation: Florida’s profitability and MLR performance below 85% reinforce the viability of TOI’s delegated approach versus peers.
- Execution Watchpoints: Investors should monitor clinic expansion, provider portal adoption, and continued pharmacy capture as capitation scales through 2026.
Conclusion
TOI’s Q1 2026 results mark a turning point, with specialty pharmacy and delegated capitation scaling as durable growth engines. Technology investments and disciplined execution are driving margin improvement and free cash flow inflection. The next phase will test TOI’s ability to operationalize growth and maximize ancillary revenue, with the provider portal and AI initiatives as key levers to watch.
Industry Read-Through
TOI’s results highlight a broader oncology industry shift toward value-based care and integrated pharmacy models as profit centers. The successful ramp of delegated capitation and pharmacy attachment rates underscores the importance of risk-bearing contracts and ancillary capture for community oncology platforms. Technology-enabled utilization management and AI-driven cost controls are becoming table stakes, with provider engagement and clinical pathway adherence as differentiators. Larger networks and MSOs may look to replicate TOI’s approach, while payers increasingly seek partners capable of managing both cost and quality in complex care. The competitive bar for operational discipline and technology leverage is rising across the sector.